Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome

Overview

About this study

This randomized pilot trial studies whether auranofin will relieve pain following paclitaxel in patients who have previously experienced paclitaxel-induced pain. Auranofin is a drug given by mouth to treat other diseases such as rheumatoid arthritis, and is being studied to see if it will decrease pain following paclitaxel.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Absolute neutrophil count (ANC) >= 1500/mm^3
  • Platelet count (PLT) >= 100,000/mm^3
  • Creatinine =< 2 x upper limit of normal (ULN)
  • Either serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) or serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x ULN
  • Total/direct bilirubin =< 1.5 x ULN
  • Alkaline phosphatase =< 1.5 x ULN
  • Hemoglobin >= 9 mg/dL
  • Negative urine or serum pregnancy test performed =< 7 days prior to registration, for women of childbearing potential only
  • Previously experienced paclitaxel induced pain during a current or past paclitaxel treatment that the treating healthcare provider thinks is consistent with the paclitaxel-induced acute pain syndrome; note: formal documentation of prior pain is not required
  • Scheduled to receive paclitaxel at a dose >= 70 mg/m^2 =< 14 days from randomization
  • Ability to complete the questionnaires or to do so with assistance

Exclusion Criteria:

  • Pregnant women
  • Nursing women
  • Any woman of childbearing potential or male partner of a woman of childbearing potential unwilling to employ acceptable contraception throughout the study and for at least 30 days after the last dose of the study drug
  • History of gold-induced disorders, including but not limited to, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasias or other severe hematologic disorders; history of severe allergic or anaphylactic reactions or hypersensitivity to auranofin or other gold compounds
  • Currently receiving Dilantin (phenytoin) or auranofin or another gold-containing compound
  • Anticipated use of filgrastim (G-CSF) or sargramostim (GM-CSF) within 30 days after receiving auranofin
  • Currently receiving immune-modulating therapies

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Aminah Jatoi, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20111740

Mayo Clinic Footer